Biotech Values

[exwannabe]

ONTY: ... to great debate as to whether this is a standard or ultra conservative share allotment boundary.

lol

On a side note, to finance AFTER the failed IA2 is clear proof that despite what Krikman said later, they thought there were decent chances of hitting on the second look.That would be inconsistent with some minute alpha spend.

Actions speak louder than words.

So we have further evidence that the trial is mucking along with a mediocre HR. Not saying it will fail, but I really doubt the numbers the ONTY bulls are hoping for will be seen.

I'll take an even money bet right now the the trial ends up with some weird geographic imbalance.